Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17319633 | 0.98 | APP (0.35) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16681847 | 0.98 | APP (0.35) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16681897 | 0.94 | CYP1A1 (0.38) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4107898 | 0.88 | APP (0.41) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL10032993 | 0.88 | APP (0.34) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1306384 | 0.87 | GABRA1 (0.38) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2866650 | 0.85 | ENPP2 (0.41) | APP | |
| SCHEMBL1306505 | 0.85 | APP (0.41) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2854252 | 0.80 | CYP1A1 (0.44) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL19174201 | 0.78 | CYP1A1 (0.48) | APPGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119774958-A | Novel seepage-proofing mortar for back water wall surface and construction process thereof | 保定禹建防水科技有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119774958-B | Novel seepage-proofing mortar for back water wall surface and construction process thereof | 保定禹建防水科技有限公司 | 2025-09-26 | — | — | CN | disclosed |
| WO-2025076285-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119774958-A | Novel seepage-proofing mortar for back water wall surface and construction process thereof | 保定禹建防水科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119774958-A | Novel seepage-proofing mortar for back water wall surface and construction process thereof | 保定禹建防水科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-107531698-B | Fused bicyclic heteroaryl derivatives having activity as PHD inhibitors | 武田药品工业株式会社 | 2024-08-13 | — | — | CN | disclosed |
| CN-115210336-B | Light absorbing material, recording medium using the same, information recording method, and information reading method | 松下知识产权经营株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-115745537-B | Light plastering mortar and preparation method thereof | 唐山盾石干粉建材有限责任公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230077155-A1 | TETRAHYDROISOQUINOLINE COMPOUND AS POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA, INC. (CN) | 2023-03-09 | — | — | US | disclosed |
| CN-115745537-A | Lightweight plastering mortar and preparation method thereof | 唐山盾石干粉建材有限责任公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2001003126-A9 | HIGH DENSITY NON-VOLATILE MEMORY DEVICE | UNIV CALIFORNIA (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1210714-A2 | HIGH DENSITY NON-VOLATILE MEMORY DEVICE | The Regents of the University of California (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6232062-B1 | HYBRIDIZATION | CLINICAL MICRO SENSORS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6221583-B1 | USE OF NUCLEIC ACIDS CONTAINING ELECTRON TRANSFER MOIETIES TO BE USED AS NUCLEIC ACID PROBES; PROBE NUCLEIC ACID IS COVALENTLY ATTACHED TO AN ELECTRODE VIA A CONDUCTIVE OLIGOMER | CLINICAL MICRO SENSORS, INC. | 2001-04-24 | — | — | US | disclosed |
| WO-2001003126-A2 | HIGH DENSITY NON-VOLATILE MEMORY DEVICE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-01-11 | — | — | WO | disclosed |
| US-6096273-A | SITE-SELECTIVE MODIFICATION OF NUCLEIC ACIDS WITH ELECTRON TRANSFER MOIETIES AND ELECTRODES, FOR GENE PROBES, MEDICAL DIAGNOSIS, TISSUE COMPATIBILITY EVALUATIONS BEFORE TRANSPLANTATION, FORENSICS | CLINICAL MICRO SENSORS (US) | 2000-08-01 | — | — | US | disclosed |
| US-6090933-A | ATTACHING THE SULFUR OF A CONDUCTIVE OLIGOMER HAVING A FIRST SUBUNIT OF A SULFUR ATOM PROTECTED BY ETHYL PYRIDINE OR TRIMETHYLSILYL ETHYL, TO THE GOLD ELECTRODE; NUCLEIC ACIDS COVALENTLY COUPLED TO ELECTRODES VIA CONDUCTIVE OLIGOMERS | CLINICAL MICRO SENSORS, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-6063573-A | SINGLE-STRANDED PROBE FOR SCREENING TARGET NUCLEOTIDE SEQUENCES | CLINICAL MICRO SENSORS, INC. (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0939762-A2 | ELECTRODES LINKED VIA CONDUCTIVE OLIGOMERS TO NUCLEIC ACIDS | Clinical Micro Sensors (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998020162-A2 | ELECTRODES LINKED VIA CONDUCTIVE OLIGOMERS TO NUCLEIC ACIDS | CLINICAL MICRO SENSORS (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077155-A1 | TETRAHYDROISOQUINOLINE COMPOUND AS POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF | KCNQ2, KCNQ1, KCNJ2 | APP 545/4885GABRA1 216/4885GABRG2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.